SABCS 2017: The latest in CDK inhibition in breast cancer
SABCS 2017: The latest in CDK inhibition in breast cancer
Autoimmune and infectious diseases among diffuse large B-cell lymphoma survivors
Autologous haematopoietic cell transplant for mantle cell lymphoma
Dexamethasone and the UKALL 2011 trial
Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients
Postmenopausal women who lose weight may have reduced breast cancer risk
Talazoparib vs physicians choice for patients with mBRCA1 breast cancer
CDK 4/6 inhibitors for older women with HR-positive breast cancer
Reducing risk of breast cancer recurrence and death with increased dose density
Breast cancer therapy resistance mediated by FGFR amplification
The significance of CEACAM 5 in metastases of triple negative breast cancer
Results of the MONALEESA 7 trial